Buyback yield (TTM)
2.22%
Shareholder yield (TTM)
2.22%
5Y share count change
4.0%
Buyback spend (TTM)
$535.80M
Cumulative buybacks
$2.60B
Key takeaways
- DexCom (DXCM) repurchased about $535.80M of stock over the trailing twelve months.
- Diluted share count is up 4.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 3.18× — repurchases more than cover SBC dilution.
- TTM repurchases used about 37% of free cash flow remaining after dividends.
Dividend & buyback yield over time for DexCom (DXCM)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for DexCom (DXCM)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for DexCom (DXCM)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for DexCom (DXCM)
Latest: $500.00M
Overview
DexCom (DXCM) most recent annual buyback spend stands at $500.00M (2025) – plunged 33.3% year-over-year.
DexCom buyback spend peaked at $750.00M in 2024; the latest annual figure is $500.00M in 2025 (33.3% below peak).
$750.00M stands as the all-time-high annual buyback spend, posted in 2024, against a low of $0.00 during 2003.
DexCom Buyback Spend 2025: $500.00M
In 2025, DexCom reported buyback spend of $500.00M, plunged 33.3% below 2024.
DexCom Buyback Spend 2024: $750.00M
DexCom buyback spend in 2024 was $750.00M, grew 8.9% from 2023. This figure represents the highest annual value in the available history.
DexCom Buyback Spend 2023: $688.70M
2023's buyback spend for DexCom came in at $688.70M, grew 23.5% from 2022.
DexCom Buyback Spend 2022: $557.70M
DexCom buyback spend in 2022 was $557.70M.
DexCom Buyback Spend 2021: $0.00
DexCom buyback spend in 2021 was $0.00.
See more financial history for DexCom (DXCM).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $500.00M | $159.60M | $340.40M | 1.95% | 0.41B | -1.7% | |
| 2024 | $750.00M | $170.40M | $579.60M | 2.42% | 0.41B | -3.0% | |
| 2023 | $688.70M | $150.80M | $537.90M | 1.44% | 0.43B | -0.5% | |
| 2022 | $557.70M | $126.50M | $431.20M | 1.27% | 0.43B | -0.3% | |
| 2021 | $0.00 | $113.40M | −$113.40M | — | 0.43B | +9.9% | |
| 2020 | $0.00 | $119.40M | −$119.40M | — | 0.39B | +5.6% | |
| 2019 | $0.00 | $102.70M | −$102.70M | — | 0.37B | +4.6% | |
| 2018 | $100.00M | $101.90M | −$1.90M | 0.94% | 0.35B | +2.2% | |
| 2017 | $0.00 | $106.20M | −$106.20M | — | 0.35B | +3.2% | |
| 2016 | $0.00 | $110.80M | −$110.80M | — | 0.33B | +4.8% | |
| 2015 | $0.00 | $82.70M | −$82.70M | — | 0.32B | +6.1% | |
| 2014 | $0.00 | $50.00M | −$50.00M | — | 0.30B | +5.8% | |
| 2013 | $0.00 | $24.60M | −$24.60M | — | 0.28B | +3.5% | |
| 2012 | $0.00 | $18.40M | −$18.40M | — | 0.27B | +4.7% | |
| 2011 | $0.00 | $13.51M | −$13.51M | — | 0.26B | +15.3% | |
| 2010 | $0.00 | $9.44M | −$9.44M | — | 0.23B | +28.3% | |
| 2009 | $0.00 | $8.37M | −$8.37M | — | 0.18B | +50.4% | |
| 2008 | $0.00 | $7.68M | −$7.68M | — | 0.12B | +4.1% | |
| 2007 | $2.73M | $6.12M | −$3.39M | 1.09% | 0.11B | +4.0% | |
| 2006 | $0.00 | $5.85B | −$5.85B | — | 0.11B | +43.8% | |
| 2005 | $0.00 | $1.67B | −$1.67B | — | 0.08B | +728.7% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 0.01B | +5.3% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 0.01B | — |
- 2025$500.00M
- 2024$750.00M
- 2023$688.70M
- 2022$557.70M
- 2021$0.00
- 2020$0.00
- 2019$0.00
- 2018$100.00M
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$0.00
- 2012$0.00
- 2011$0.00
- 2010$0.00
- 2009$0.00
- 2008$0.00
- 2007$2.73M
- 2006$0.00
- 2005$0.00
- 2004$0.00
- 2003$0.00
Buybacks vs stock-based compensation for DexCom (DXCM)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.18×.
Buybacks vs dividends (share of cash returned) for DexCom (DXCM)
How DexCom splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as DexCom, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.43B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation